Ensysce Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $6.56M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | – | $-0.20 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | After market close | – | $-0.75 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | After market close | – | $-0.79 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | – | $-1.39 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 10, 2025 | After market close | – | $-2.90 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 15, 2024 | Before market open | – | – | – |
Press releases
Announcements Ensysce Biosciences filed with the SEC
Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Biosciences Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Biosciences Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
Results of operations · EX-99.1 to Form 8-K
Biosciences Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences, Inc. Announces Exercise of
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biosciences, Inc. Announces $1.1 Million Registered Direct
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences, Inc. Announces $5 Million Concurrent Registered Direct
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Ensysce Biosciences Reports Second Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Biosciences Regains Compliance with Nasdaq
Other events · EX-99.1 to Form 8-K
Biosciences Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biosciences Postpones Special Meeting of Stockholders to December 29, 2023
Other events · EX-99 to Form 8-K
Biosciences Announces Completion of $1.7 Million Convertible Note Financing
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Secures $1.7 Million Convertible Note Financing
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Regains Compliance with Nasdaq
Other events · EX-99.1 to Form 8-K
Biosciences, Inc. Announces Closing of $7 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences, Inc. Announces $3 Million Registered Direct Offering
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Biosciences Announces the Distribution of Series A Preferred Stock to Holders of its Common Stock
Charter or bylaw amendment · Regulation FD disclosure · EX-99 to Form 8-K
EX-99 to Form 8-K
Other events · EX-99 to Form 8-K
Biosciences Announces Pricing of $4.1 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614
Other events · EX-99.1 to Form 8-K
Biosciences Announces Results of Special Meeting of Stockholders
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Completion of $8 Million Convertible Note Financing
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Secures $8 Million Convertible Note Financing
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K